<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856452</url>
  </required_header>
  <id_info>
    <org_study_id>NCC-1110212-2</org_study_id>
    <nct_id>NCT01856452</nct_id>
  </id_info>
  <brief_title>Comparison Study of Sentinel Lymph Node Biopsy by Multimodal Method in Breast Cancer</brief_title>
  <official_title>Phase II Study of Comparison of Sentinel Lymph Node Biopsy Guided by The Multimodal Method of Indocyanine Green Fluorescence, Radioisotope and Blue Dye Versus the Radioisotope in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sentinel lymph node biopsy (SLNB) has become a mainstay surgery method in breast cancer. It
      provides the surgeon the evidence of axillary lymph node metastasis, which determines the
      extent of surgery. Because effective SLNB can decrease the extent of axillary lymph node
      dissection, it is increasingly important. In general, radioactive colloid has been used for
      SLNB. In order to pursue more precise SLNB, the investigators developed a multimodal method
      enabling visual guidance with the mixture of indocyanine green, blue dye and radioisotope.

      In this study, our hypotheses are as following:

        1. Multimodal method enables to increase identification rate of SLNB

        2. blue dye and indocyanine green provide the surgeon visual guidance to ensure better
           outcome

        3. Multimodal method alleviates the shortcomings of indocyanine green and blue dye as an
           identification strategy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Indocyanine green Advantages: provides visualization of sentinel lymph node without incision

      Blue dye Advantages: easy to employ; no toxicity Disadvantages: diffusion; absorption and
      disappearance of the marking within minutes

      Radioisotope Advantages: can be used for lesions not accessible to Ultrasound; ideal for
      selective uptake to sentinel lymph node Disadvantages: not able to use palpation and
      visualization, confirms by gamma-probe only
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to sentinel lymph node biopsy</measure>
    <time_frame>up to 6 months</time_frame>
    <description>From the date of randomization, skin necrosis and dye staining are assessed up to 6 months after the operation (post op 3 mon and 6 mon follow-up).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification rate of sentinel lymph node biopsy</measure>
    <time_frame>13 months</time_frame>
    <description>The number of participants with sentinel lymph node detection is assessed up to 13 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>radioisotope</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sentinel lymph node operation using radioisotope in the breast cancer patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the mixture including indocyanine green</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sentinel lymph node operation using the mixture of indocyanine green, blue dye and radioisotope in the breast cancer patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>the mixture including indocyanine green</intervention_name>
    <description>Sentinel lymph node biopsy using near-infrared imaging system and gamma probe detector for the mixture of indocyanine green, blue dye, and radioisotope during operation</description>
    <arm_group_label>the mixture including indocyanine green</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>radioisotope</intervention_name>
    <description>Sentinel lymph node biopsy using gamma probe detector for radioisotope during operation</description>
    <arm_group_label>radioisotope</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinically lymph node negative breast cancer patients

          -  consented patients with more than 20 years

        Exclusion Criteria:

          -  history of breast cancer

          -  locally advanced breast cancer and metastatic breast cancer

          -  proven axillary lymph node metastasis

          -  history of axillary excisional or incisional biopsy, or dissection

          -  history of neoadjuvant chemotherapy

          -  pregnancy

          -  non-consented patients

          -  younger than 20 years old
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>So-Youn Jung</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>So-Youn Jung</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>Sentinel lymph node</keyword>
  <keyword>multimodal</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

